Keywords
1. Lipoprotein(a)
2. Atherosclerosis
3. Cardiovascular Risk
4. PCSK9 inhibitors
5. Antisense Oligonucleotide Therapy
The association between Lipoprotein(a), commonly referred to as Lp(a), and atherosclerotic cardiovascular disease (ASCVD) has long intrigued researchers and clinicians alike. Originally discovered in 1963, Lp(a) is a unique apolipoprotein B-containing lipoprotein, which carries a structural resemblance to LDL (low-density lipoprotein) yet evades the designation of a conventional cardiovascular risk factor due to a lack of substantial evidence tying its reduction to clinical benefits. However, recent developments in the field suggest that the narrative around Lp(a) is slated for a notable revision. This article delves into these advances, guided by the research contributions of Hayato Tada, Masayuki Takamura, and Masa-Aki Kawashiri, and outlines how Lp(a) is shifting from a mere biomarker to a potential therapeutic target.
Current Understanding of Lipoprotein(a)
Lp(a) is composed of an LDL-like particle bonded to apolipoprotein(a), or apo(a), via a disulfide bond. The concentration of Lp(a) in the blood has been flagged as an independent risk factor for ASCVD, implicating it in conditions such as coronary artery disease and aortic valve stenosis. Lp(a) concentrations are primarily genetically determined, with minor influence from diet, exercise, or other environmental factors. Clinical trials have consistently demonstrated that individuals with elevated Lp(a) levels are at increased risk for ASCVD. However, until the advent of novel lipid-lowering agents, there were scant means available to effectively reduce Lp(a) levels.
Reevaluating Lipoprotein(a) as a Causal Risk Factor
The relationship between Lp(a) and ASCVD is not merely associative, as corroborated by Mendelian randomization studies, which suggest a causative link. Elevated levels of Lp(a) have been associated with increased risk of myocardial infarction and calcific aortic valve stenosis, driven potentially by the peculiar properties of Lp(a) to promote thrombosis and impede fibrinolysis while fostering a pro-inflammatory milieu.
Traditional Lipid-lowering Therapies and Lipoprotein(a)
Standard lipid-lowering therapies such as statins have limited impact on Lp(a) concentrations. Niacin was among the first agents proven to reduce Lp(a) levels; however, its adverse effects and a lack of clear evidence correlating Lp(a) reduction with improved clinical outcomes led to skepticism regarding its utility. The subsequent development of PCSK9 inhibitors, however, has renewed interest in the therapeutics of Lp(a). These novel biologic agents not only significantly lower LDL cholesterol but also exhibit a profound ability to reduce Lp(a) levels.
Emerging Therapeutics Targeting Lipoprotein(a)
The most promising therapeutic interventions designed to lower Lp(a) directly target apo(a). Antisense oligonucleotides are novel synthetic molecules that degrade the precursor RNA molecules, leading to a marked decrease in the synthesis of their protein products. Clinical trials with antisense oligonucleotides directed against apo(a) have yielded promising results, showcasing substantial Lp(a) level reductions and signaling a potential new horizon in managing ASCVD risk.
Furthermore, the effects of new LDL cholesterol-lowering drugs, such as evolocumab, on Lp(a) and the potential modification of Lp(a) particle kinetics provide deeper insights into the complex metabolic processes influenced by Lp(a) targeting therapies. The integration of genetic testing in clinical assessment may pave the way for patient-specific mandates in cardiovascular risk management strategies.
Clinical Implications and Future Perspectives
The lingering conundrum of Lp(a) as a therapeutic target mostly stems from the absence of large randomized controlled trials demonstrating that Lp(a) lowering culminates in a reduction of cardiovascular events. However, this stands to change with the ongoing clinical trials designed to address this critical question specifically. If these trials echo the assertion of Lp(a) as a causative factor in ASCVD, the clinical implications could be vast, inviting more aggressive screening approaches and the establishment of Lp(a) as a legitimate target in the lipid management arsenal.
Concluding Remarks and DOI
In conclusion, the burgeoning body of evidence positions Lp(a) as both an old and a new causal risk factor for ASCVD. The excitation surrounding Lp(a)-specific therapies marks an exhilarating juncture in cardiovascular disease management, embedding within the broader understanding of ASCVD as a genetically influenced and therapeutically tractable malady. The revisitation of Lp(a) in light of these novel therapeutics may potentially redraw cardiovascular risk reduction strategies, recasting an erstwhile underappreciated factor into a protagonist role in the saga of atherosclerosis mitigating endeavors.
DOI: 10.5551/jat.RV17034
References
1. Reith C, Armitage J. Management of residual risk after statin therapy. Atherosclerosis, 2016; 245: 161-170. DOI: 10.1016/j.atherosclerosis.2015.11.035.
2. Cannon CP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med, 2015; 372: 2387-2397. DOI: 10.1056/NEJMoa1410489.
3. Kamstrup PR, et al. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol, 2013; 61: 1146-1156. DOI: 10.1016/j.jacc.2012.12.023.
4. Clarke R, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med, 2009; 361: 2518-2528. DOI: 10.1056/NEJMoa0902604.
5. CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet, 2013; 45: 25-33. DOI: 10.1038/ng.2480.